GlassScriptPhysician profile
Edward Amoah
NPI 1336101450
$2,130.41
in general payments reported to CMS, 2019-2025
20 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $137 · 2021: $449 · 2022: $429 · 2023: $156 · 2024: $243 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.39 | 2021-2025 | Vraylar, Qulipta |
| Pfizer INC. | $268.13 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $172.72 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $132.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.75 | 2025 | |
| Glaxosmithkline, LLC. | $114.22 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $114.03 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.80 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.99 | 2025 | Caplyta |
| Abbott Laboratories | $93.46 | 2021-2025 | Freestyle Libre 3 |
| Braeburn INC. | $82.56 | 2023-2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.65 | 2021 | |
| Novo Nordisk INC | $52.86 | 2022-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $46.34 | 2020-2021 | |
| Lilly USA, LLC | $39.06 | 2024-2025 | Mounjaro, Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $31.19 | 2020-2021 | |
| Allergan, INC. | $26.21 | 2019-2020 | |
| Indivior INC. | $14.98 | 2019 | |
| Dexcom, INC. | $14.43 | 2021 | |
| Exact Sciences Corporation | $13.18 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Amoah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.